Bank of America Downgrades Entellus Medical Inc to Underperform

Brokerage firm Bank of America Downgrades its rating on Entellus Medical Inc(ENTL). The shares have been rated Underperform. Previously, the analysts had a Buy rating on the shares. The rating by the stock financial advisor at Bank of America was issued on Feb 22, 2017 in a research report to their Investors and Clients.

Entellus Medical Inc (ENTL) shares turned negative on Wednesdays trading session with the shares closing down -4.58 points or -26.81% at a volume of 12,39,579. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $14.7231. The peak price level was also seen at $14.7231 while the days lowest was $12.5. Finally the shares closed at $12.5. The 52-week high of the shares is $22.63 while the 52-week low is $12.5. According to the latest information available, the market cap of the company is $265 M.

Entellus Medical Inc(ENTL) last announced its earnings results on Aug 3, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $18.73M. Analysts had an estimated revenue of $18.48M. Earnings per share were $-0.27. Analysts had estimated an EPS of $-0.35.

Several Insider Transactions has been reported to the SEC. On Jan 18, 2017, Karen E Peterson (VP, Regulatory & Quality) sold 10,000 shares at $20.13 per share price.Also, On Jan 18, 2017, Brian E Farley (director) sold 14,019 shares at $20.14 per share price.On Oct 14, 2016, Margaret A Boiano (VP Healthcare Policy&Reimburse) sold 11,103 shares at $20.01 per share price, according to the Form-4 filing with the securities and exchange commission.

Entellus Medical Inc. is a medical technology company. The Company is focused on the design development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear nose and throat (ENT) physicians to open narrowed or obstructed sinus drainage pathways using balloon sinus dilation to treat patients with symptomatic inflammation of the nasal sinuses. Its XprESS family of products includes its XprESS Pro device its XprESS LoProfile device and its XprESS Ultra device. The Company markets its products in the United States and Canada and sells its products through a direct sales force in the United States.

Add Comment